



Malassezia in the central nervous system and multiple sclerosis

Julián Benito-León^{1,2,3} · Martin Laurence⁴

Received: 19 July 2018 / Accepted: 14 August 2018 / Published online: 17 August 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

We read with interest the review about fungal infections of the central nervous system (CNS) by Górska et al. [1]. Our interest stems from the many recently discovered links between fungi and idiopathic inflammatory diseases [2] including multiple sclerosis (MS) [3, 4]. Górska et al. review is very thorough, and covers nearly all medically important fungi [1]. However, the most common fungal genus present in humans, *Malassezia*, is not mentioned. *Malassezia* infections of the CNS can result in severe illness [5]. Like all infections of the CNS, *Malassezia* infections which cause acute neurological symptoms are rare and often associated with immunosuppression [5]. *Malassezia* are difficult to detect: they are small, fastidious, resistant to lysis and their ribosomal genes mismatch commonly used consensus primers [2]. This suggests *Malassezia*-induced neurological symptoms may often be missed.

Malassezia are usually described as ubiquitous commensals of mammalian skin. Improved detection techniques based on deep sequencing have led to the detection of *Malassezia* in many human organs [2] including the CNS [6, 7]. We overlooked these key studies in our recent article summarizing the links between fungi and MS [4]. This omission is important because *Malassezia* is the only known fungal genus which has all the right properties to cause MS [4]: it has been reported present in the mouth, gut and CNS, and its association with spondyloarthritis and Crohn's disease suggests it first colonizes the gut of young adults [2], mirroring the age at onset of MS. The paucity of pediatric

MS cases—despite ample childhood exposure to most infections including the Epstein–Barr virus and fungi—has long puzzled us [4]. We now realize that *Malassezia*'s absence from the gut of children could explain their low risk of MS.

Malassezia appear to be ubiquitous in the mouth, nose, gut and breast of healthy adults [2], suggesting this genus may colonize many internal organs. Though small studies report finding *Malassezia* in the CNS [6, 7], these data are too preliminary to estimate its prevalence. Reliable techniques to detect fungi in the CNS should be designed to cover *Malassezia* in addition to other medically important fungi. Future studies attempting to confirm that *Malassezia* colonizes the mouth, gut and CNS should use techniques which are less susceptible to contamination, such as fluorescent *in situ* hybridization (FISH) and immunohistochemistry (IHC). The adaptive immune response against *Malassezia* should be tested in MS case-control studies by measuring antibodies against *Malassezia* antigens, and by measuring memory B cell and CD4+ T cell recognition of *Malassezia* antigens. Finally, a clinical study should be run to test the efficacy of voriconazole in MS, similarly to itraconazole in Crohn's disease [8].

Compliance with ethical standards

Conflict of interest We declare no competing interests.

References

1. Górska K, Błazkowska J, Dzikowiec M. Neuroinfections caused by fungi. *Infection*. 2018;46(4):443–59. <https://doi.org/10.1007/s15010-018-1152-2>.
2. Laurence M, Asquith M, Rosenbaum JT. Spondyloarthritis, acute anterior Uveitis and fungi: updating the Catterall King hypothesis. *Front Med*. 2018. <https://doi.org/10.3389/fmed.2018.00080>.
3. Benito-León J, Pisa D, Alonso R, Calleja P, Díaz-Sánchez M, Carrasco L. Association between multiple sclerosis and *Candida* species: evidence from a case-control study. *Eur J Clin Microbiol Infect Dis*. 2010;29(9):1139–45. <https://doi.org/10.1007/s10096-010-0979-y>.

✉ Julián Benito-León
jbenitol67@gmail.com

¹ Department of Neurology, University Hospital “12 de Octubre”, Avda. de la Constitución 73, portal 3, 7º Izquierda, 28821 Coslada, Madrid, Spain
² Department of Medicine, Faculty of Medicine, Complutense University, Madrid, Spain
³ Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
⁴ Shipshaw Labs, Montreal, QC, Canada

4. Benito-León J, Laurence M. The role of fungi in the etiology of multiple sclerosis. *Front Neurol.* 2017;8:535. <https://doi.org/10.3389/fneur.2017.00535>.
5. Olar A, Shafi R, Gilger M, Stager C, Moss J, Schady D, et al. Central nervous system involvement by *Malassezia restricta*, an unusual fungal pathogen: a report of two cases. *Neurology.* 2012;78(1 Supplement):P01.245.
6. Alonso R, Pisa D, Marina AI, Morato E, Rábano A, Carrasco L. Fungal infection in patients with Alzheimer's disease. *J Alzheimer's Dis.* 2014;41(1):301–11. <https://doi.org/10.3233/JAD-132681>.
7. Alonso R, Fernández-Fernández AM, Pisa D, Carrasco L. Multiple sclerosis and mixed microbial infections. Direct identification of fungi and bacteria in nervous tissue. *Neurobiol Dis.* 2018;117:42–61. <https://doi.org/10.1016/j.nbd.2018.05.022>.
8. Samuel S, Loftus E Jr, Sandborn W. The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis. *Aliment Pharmacol Ther.* 2010;32(9):1207–9. <https://doi.org/10.1111/j.1365-2036.2010.04444.x>.